Copperwynd Financial LLC Sells 272 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Copperwynd Financial LLC lessened its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5.7% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,506 shares of the pharmaceutical company’s stock after selling 272 shares during the period. Vertex Pharmaceuticals comprises 0.7% of Copperwynd Financial LLC’s holdings, making the stock its 26th largest holding. Copperwynd Financial LLC’s holdings in Vertex Pharmaceuticals were worth $2,234,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the business. University of Texas Texas AM Investment Managment Co. acquired a new stake in Vertex Pharmaceuticals during the fourth quarter worth approximately $25,000. GHP Investment Advisors Inc. acquired a new position in Vertex Pharmaceuticals in the second quarter valued at about $29,000. Annapolis Financial Services LLC bought a new stake in Vertex Pharmaceuticals during the first quarter worth about $27,000. Stephens Consulting LLC acquired a new stake in Vertex Pharmaceuticals during the second quarter worth about $31,000. Finally, ICA Group Wealth Management LLC acquired a new stake in Vertex Pharmaceuticals during the fourth quarter worth about $28,000. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ VRTX opened at $462.88 on Friday. The company has a quick ratio of 2.26, a current ratio of 2.52 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $119.45 billion, a PE ratio of 30.04 and a beta of 0.40. The firm has a fifty day simple moving average of $479.92 and a 200 day simple moving average of $453.85. Vertex Pharmaceuticals Incorporated has a twelve month low of $341.85 and a twelve month high of $510.64.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Thursday, August 1st. The pharmaceutical company reported ($12.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($12.54) by ($0.29). Vertex Pharmaceuticals had a negative net margin of 4.74% and a negative return on equity of 2.45%. The business had revenue of $2.65 billion during the quarter, compared to analyst estimates of $2.66 billion. During the same period in the prior year, the firm earned $3.53 earnings per share. The firm’s revenue for the quarter was up 6.1% compared to the same quarter last year. On average, sell-side analysts forecast that Vertex Pharmaceuticals Incorporated will post -2.14 EPS for the current year.

Insiders Place Their Bets

In other news, Chairman Jeffrey M. Leiden sold 3,784 shares of Vertex Pharmaceuticals stock in a transaction on Friday, August 30th. The shares were sold at an average price of $499.00, for a total value of $1,888,216.00. Following the completion of the sale, the chairman now owns 9,994 shares in the company, valued at approximately $4,987,006. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Chairman Jeffrey M. Leiden sold 3,784 shares of the business’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $499.00, for a total value of $1,888,216.00. Following the completion of the sale, the chairman now directly owns 9,994 shares of the company’s stock, valued at approximately $4,987,006. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Sangeeta N. Bhatia sold 646 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $500.00, for a total value of $323,000.00. Following the completion of the transaction, the director now owns 4,435 shares in the company, valued at approximately $2,217,500. The disclosure for this sale can be found here. In the last three months, insiders have sold 31,767 shares of company stock worth $15,768,284. Corporate insiders own 0.20% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. StockNews.com downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, August 5th. JPMorgan Chase & Co. lifted their price target on Vertex Pharmaceuticals from $505.00 to $510.00 and gave the company an “overweight” rating in a research note on Monday, August 5th. Cantor Fitzgerald restated an “overweight” rating and set a $480.00 price objective on shares of Vertex Pharmaceuticals in a research report on Friday, August 2nd. Truist Financial reiterated a “buy” rating and issued a $550.00 target price (up previously from $508.00) on shares of Vertex Pharmaceuticals in a research report on Monday, August 5th. Finally, Needham & Company LLC restated a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Friday, July 26th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $486.36.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.